Long-term treatment with rituximab — a cancer drug used despite not having specific approval — is safe and generally effective for controlling IgG4-related disease (IgG4-RD), though researchers say more study is needed to standardize its use. Those are the outcomes of a small study by scientists in Germany, who…
